IMARA Inc. (IMRA) financial statements (2022 and earlier)

Company profile

Business Address 116 HUNTINGTON AVENUE
BOSTON, MA 02116
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:90,300102,80066,80075,60088,20096,100106,300
Cash and cash equivalents48,30975,29548,03753,44147,69834,15854,651
Short-term investments41,96927,54418,73122,15140,52461,93151,624
Other undisclosed cash, cash equivalents, and short-term investments22(39)328(22)1125
Deferred costs   200   
Other undisclosed current assets2,3963,1974,5574,5612,2053,6114,293
Total current assets:92,696105,99771,35780,36190,40599,711110,593
Noncurrent Assets
Operating lease, right-of-use asset525580637694   
Property, plant and equipment250275299324349376400
Other noncurrent assets1751751753088888324
Total noncurrent assets:9501,0301,1111,326437464724
TOTAL ASSETS:93,646107,02772,46881,68790,842100,175111,317
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,9646,9386,7195,2466,2475,3104,848
Accounts payable2,3602,4762,6263,0011,9711,8861,669
Accrued liabilities4,6044,4624,0932,2454,2763,4243,179
Other undisclosed current liabilities246250254257   
Total current liabilities:7,2107,1886,9735,5036,2475,3104,848
Noncurrent Liabilities
Long-term debt and lease obligation406466528590   
Operating lease, liability406466528590   
Liabilities, other than long-term debt    160167173
Deferred rent credit    160167173
Other undisclosed noncurrent liabilities(406)(466)(528)(590)   
Total noncurrent liabilities: 466528590160167173
Total liabilities:7,6167,6547,5016,0936,4075,4775,021
Stockholders' equity
Stockholders' equity attributable to parent86,03099,37364,96775,59484,43594,698106,296
Common stock27271918181818
Additional paid in capital233,516232,526184,479181,945180,526179,251178,402
Accumulated other comprehensive income (loss)(16)(2) 142448
Accumulated deficit(147,497)(133,178)(119,531)(106,370)(96,113)(84,595)(72,172)
Total stockholders' equity:86,03099,37364,96775,59484,43594,698106,296
TOTAL LIABILITIES AND EQUITY:93,646107,02772,46881,68790,842100,175111,317

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Operating expenses(14,334)(13,659)(13,169)(10,280)(11,550)(12,494)(10,302)
Operating loss:(14,334)(13,659)(13,169)(10,280)(11,550)(12,494)(10,302)
Nonoperating income1512823327198
Other nonoperating expense(57)(18)(40)(60)(83)(55)(12)
Net loss available to common stockholders, diluted:(14,319)(13,647)(13,161)(10,257)(11,518)(12,423)(10,204)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net loss:(14,319)(13,647)(13,161)(10,257)(11,518)(12,423)(10,204)
Comprehensive loss:(14,319)(13,647)(13,161)(10,257)(11,518)(12,423)(10,204)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(14)(2)(1)(3)(20)(24)64
Comprehensive loss, net of tax, attributable to parent:(14,333)(13,649)(13,162)(10,260)(11,538)(12,447)(10,140)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: